This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
by Zacks Equity Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
VIR Stock Down on Another Setback for COVID-19 Antibody
by Zacks Equity Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
by Zacks Equity Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
by Zacks Equity Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
by Zacks Equity Research
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
by Zacks Equity Research
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
VIR vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VIR vs. ILMN: Which Stock Is the Better Value Option?
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Vir Biotechnology, Inc. (VIR)
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment
by Zacks Equity Research
VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.
Vir Biotechnology, Inc. (VIR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
by Zacks Equity Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Universal Health (UHS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
Avid (CDMO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Vir Biotechnology, Inc. (VIR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Dynavax's (DVAX) Growth Momentum Continue in 2022?
by Zacks Equity Research
Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.
Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
Gilead (GILD) Veklury Retains Activity Against Omicron Variant
by Zacks Equity Research
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
Will Patient Days Drive Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.